Pharma felon Martin Shkreli got a dose of reality Friday when a Brooklyn judge slapped him with seven years behind bars for securities fraud.
Brooklyn federal court judge Kiyo Matsumoto handed down the sentence to the ever-arrogant 34-year-old after he broke down into tears as he made one last plea for leniency.
“I was never motivated by money. I was trying to grow my stature and reputation,” he blubbered in court. “I took down Martin Shkreli with my disgraceful and shameful actions. This is my fault. I’m not a victim here.”
A jury returned a mixed verdict against the notorious felon last August, convicting him of defrauding investors in a series of his hedge funds, MSMB Capital and MSMB Healthcare.
The government claimed he’d also looted his drug company Retrophin to pay back the investors after he lost their money in a bad trade. He was acquitted of that allegation.
Shkreli’s lawyers asked for a more lenient sentence of 12 to 18 months with community service — insisting that the failed pharmaceutical exec was remorseful and a changed man.
Shkreli’s lawyer Ben Brafman implored the judge for nearly an hour not to sentence the loudmouth “simply for being Martin Shkreli.”
“There are times when I want to hug him and hold him and comfort him,” Brafman said, “and there are times I want to punch him in the face.”
Prosecutors wanted at least 15 years, which the defense blasted as “draconian.”
Following his conviction on three out of eight counts, Shkreli boasted about dodging jail — or, at the very worst, being sentenced to a cushy, minimum-security federal prison camp he called “Club Fed.”
“I’d say there’s a good chance there’s no jail at all,” he told his followers on a livestream.
Shkreli has been cooling his heels at Brooklyn Metropolitan Detention Center as Inmate No. 87850-053 since September after the judge revoked his bail for setting a $5,000 bounty for a strand of Hillary Clinton’s hair.
Defense plans to appeal Shkreli’s conviction.
Shkreli became known as the “most hated man in America” for jacking up the price of potentially life-saving drug Daraprim by 5,000 percent — and boasting about it.
Additional reporting by Lia Eustachewich